Panion & Bf Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Panion & Bf Biotech şirketinin toplam hissedar öz sermayesi NT$1.9B ve toplam borcu NT$725.6M olup, bu da borç-öz sermaye oranını 39.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$3.3B ve NT$1.4B dir. Panion & Bf Biotech 'in FAVÖK'ü NT$193.4M faiz karşılama oranı 207 dur. Şirketin NT$581.9M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

39.1%

Borç/özkaynak oranı

NT$725.56m

Borç

Faiz karşılama oranı	207x
Nakit	NT$581.86m
Eşitlik	NT$1.85b
Toplam yükümlülükler	NT$1.40b
Toplam varlıklar	NT$3.25b

Son finansal sağlık güncellemeleri

Recent updates

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Aug 13

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Apr 07

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Mar 03

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

Feb 04

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

Jan 09

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Dec 14

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1760 'nin kısa vadeli varlıkları ( NT$1.5B ) kısa vadeli yükümlülüklerini ( NT$1.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: 1760 şirketinin kısa vadeli varlıkları ( NT$1.5B ) uzun vadeli yükümlülüklerini ( NT$272.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1760 'nin net borç/öz sermaye oranı ( 7.8% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 1760 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 39.1% seviyesine yükseldi.

Borç Kapsamı: 1760 'nin borcu işletme nakit akışı ( 40.7% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 1760 'in borcuna ilişkin faiz ödemeleri EBIT ( 207 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Panion & Bf Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Recent updates

Panion & Bf Biotech Inc. to Report Q3, 2024 Results on Nov 12, 2024

Second quarter 2024 earnings released: EPS: NT$0.23 (vs NT$0.20 in 2Q 2023)

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Panion & Bf Biotech Inc. to Report Q2, 2024 Results on Aug 13, 2024

Upcoming dividend of NT$1.50 per share

Panion & Bf Biotech Inc. Announces the Cash Dividend, Payable on July 10, 2024

Panion & Bf Biotech Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$0.90 (vs NT$2.13 in FY 2022)

Panion & Bf Biotech Inc., Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Panion and BF Biotech Inc. Obtains Nephoxil NDA Approval

Panion & Bf Biotech Inc. Announces Nephoxil Receives NMPA Acceptance for NDA Application Submission

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$1.88 in 2Q 2022)

Upcoming dividend of NT$2.00 per share at 1.5% yield

Panion & Bf Biotech Inc. Announces the Cash Dividend, payable on August 11, 2023

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released: EPS: NT$2.13 (vs NT$1.32 in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: NT$0.91 (vs NT$0.77 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.88 (vs NT$0.97 in 2Q 2021)

Upcoming dividend of NT$1.50 per share

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: NT$0.46 (vs NT$0.32 loss in 1Q 2021)

Price target increased to NT$106

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS NT$0.77 (vs NT$0.038 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.97 (vs NT$0.099 loss in 2Q 2020)

Upcoming dividend of NT$0.70 per share

Price target increased to NT$108

First quarter 2021 earnings released: NT$0.32 loss per share (vs NT$0.009 profit in 1Q 2020)

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Full year 2020 earnings released: EPS NT$0.36 (vs NT$2.10 in FY 2019)

Panion & Bf Biotech Inc., Annual General Meeting, Jun 04, 2021

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

New 90-day low: NT$74.10

Price target lowered to NT$97.00

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

New 90-day low: NT$80.60

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

New 90-day low: NT$91.10

Third quarter 2020 earnings released: NT$0.04 loss per share

Revenue misses expectations

New 90-day low: NT$104

New 90-day low: NT$112

Price target raised to NT$141

First half earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin